Investment Q&A

Q: Saw the analyst’s downgrade of Fiera and the resulting 5%+ drop in the company’s share price today (Monday). Do you believe the rationale for the downgrade to be valid? Is it still worth holding? Do you still have Fiera in any of your model portfolios? Thanks as always.

Q: Would you buy the dip today
Thanks
Karim

Q: Does this move downwards provide a nice entry point given the circumstances?

Q: Gentlemen Good Morning,
Brokers are lying on dividends paid in US$
I phoned to Computershare the 'Agent' to ask about the dividends from CSU.
From CSU web site : Computershare is the agent of CSU, the dividends are paid in US$
16-03-2019 05-04-2019 USD $21.00 Third Party Cheque, Cheque Y COMMON

Q: Do you think the proposed nomination of the new directors gets approved by share holders ?
If so, could the new board replace Mr. Goodman.
Can you elaborate as to what is most likely to happen in the next few months ?
Thanks for your advice.

Q: My allocation in the consumer category is at its maximum. Would a swap of NFI for GIL make sense?

Q: I hold SIS and also disappointed, but I did purchase at $5.72 so I will watch for now. PLC announced an offering: Park Lawn Corporation Announces $125 Million Bought Deal Offering and Successful Completion of Cress Funeral Service Acquisition. Stock down 6.75%, is this an opportunity to purchase PCL at a discount?
Thanks

Q: Any comment on the Park Lawn stock issue?

Thanks.

Q: Looking for the reason for the halt trade?
Mike

Q: re fund raise this bourassa is just nasty, they just raised money, i am gone as of today.dave

Q: I would like to know if there is any "hanky panky" going on with
SIS and Dejardins. SIS got upgraded by Dejardins from $16 to $17.50 on an earnings miss which made the stock go up over $15. Now Dejardins are the underwriters
of this deal. Also does this type of "you scratch my back and I'll scratch yours"
happen often in the markets?

Q: Please comment on TFII's acq.of Aulick Leasing & Shirail LLC today.Txs for u usual great services & views

Q: Is ENB still safe to hold as Michigan governor Gretchen Whitmer has stopped work on line 5 beneath the Straits of Mackinac and might stop oil and gas flow altogether.

Q: Medison(7.3% shareholder) is nominating 6 (qualified members per co) plus its CEO(existing director) to the board of GUD(total 7 seats).Maybe this will result in positive price action for long suffering investors who bought in the $10 range.Your comment please.Thanks for u usual great services & views

Q: What are your thoughts on the bought deal private placement of 5M shares? If this was a less common occurrence it would be acceptable but SIS just raised money last year. On both occasions they wait for the share price to get to around $15/$16 and they decide to raise money and drive the share price down. They have set a ceiling on the share price and everytime it gets momentum they send it falling back down to earth. It seems to me that they raise the dividend to drive up the share price only to dilute our shares to get more money. If you need money why raise the dividend 20%, why not keep it the same or slight raise to save money and stop diluting and let the share price go above $16. I've liked mgmt but I'm starting to lose confidence in their decisions around growth. They have just ensured that the share price will fall to $14 tomorrow and stay in that range for months to come. Same as last year. Sorry, frustrated with the recurring dilution. Thanks

Q: Follow-up on my earlier post today relevant to a possible reason for COVALON's 10% jump in stock price: The Zacks report a COV director sent to investors this morning (as an email attachment) is dated: March 18, 2019, and was authored by Brian Marckx, CFA, with Zacks Small Cap Research. While there may be an old Zacks report out there, this one appears to be new.

Q: Jeffrey Mandel (a director on Covalon's Board) sent one of his periodic e-mails directly to COV investors. Today's message included a PDF attachment of a 25pp research document COV apparently commissioned from Zacks Small Cap Research in Chicago. Unsurprisingly, the analysis is glowing, which stated, in part, "We forecast Covalon to generate revenue and EPS of C$53.4M and C$0.13 in 2019 and C$64.5M and C$0.30 in 2020. We value Covalon using a combination of P/S and P/E methodologies. Based on analyst's revenue and EPS estimates of publicly traded companies in focused on wound care and medical supplies, infection control and vascular products, we calculate fair value of Covalon at ~C$11.2/share, or US$8.50 based on current exchange rates."

Q: what is the connection between these 2 companies?
thanks.

Q: Hi Team,

Could you tell us the story behind today's 10% jump please.

Thanks!

Q: FSZ has taken quite a beating today. Any idea what's causing it? Time to buy more?